Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
Apple Turns 50: From Garage Startup to AI Crossroads 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Britain Courts Anthropic Amid US Defense Department Dispute 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
NEW YORK, Nov. 25, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the Southern District of California on behalf of investors who purchased Ligand Pharmaceuticals Inc. (NASDAQ:LGND) securities between November 9, 2015 and November 14, 2016.
Click here to learn about the case: http://www.wongesq.com/pslra/ligand-pharmaceuticals. There is no cost or obligation to you.
According to the complaint, during the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Ligand overstated the value of certain Deferred Tax Assets by approximately $27.5 million; (2) Ligand’s outstanding convertible senior unsecured notes due 2019 should have been classified as short-term debt rather than long-term debt as of December 31, 2015; (3) Ligand did not maintain effective controls over the accuracy and presentation of the accounting for income taxes related to complex transactions; (4) in turn, Ligand lacked effective internal control over financial reporting; and (5) as a result, Defendants’ statements about Ligand’s business, operations and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.
If you suffered a loss in Ligand you have until January 17, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra/ligand-pharmaceuticals.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
